News

CellVoyant and Automata announce a strategic partnership integrating the FateDrive™ AI platform with Automata’s LINQ™ lab automation system to enable autonomous, closed-loop bioprocess optimization.

This case study showcases the integration of CellVoyant’s AI models with Automata’s LINQ™ platform to enable adaptive, closed-loop cell culture automation based on real-time cellular analysis.

CellVoyant was featured in Fortune magazine in an article by AI Editor Jeremy Kahn, highlighting the company’s vision to transform cell-based therapeutics using AI and the FateView™ technology.

CellVoyant was named the Innovation Incubator Winner for 2025 at the AI Drug Discovery & Development Summit for its work applying AI to label-free live-cell imaging and predictive cell analytics.

FateView™ the first online platform enabling AI-driven, predictive live cell analytics was publicly launch in September with a one-month free trial for new users.